FDA Accepts TransCon® CNP NDA for Priority Review
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/16/2026
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Netflix earnings forecast disappoints Wall Street, shares tumble
- Alphabet stock falls on report of Gemini AI model delays
- TSMC Q2 profit jumps 77% to record, far surpasses expectations
- Oil settles lower, but remains near one-month high on U.S.-Iran tension
Ascendis Pharma (ASND) PT Raised to $201 at BofA Securities
June 2, 2025 12:02 PM EDTBofA Securities analyst Tazeen Ahmad raised the price target on Ascendis Pharma (NASDAQ: ASND) to $201.00 (from $196.00) while maintaining a Buy rating.
The analyst comments "Ascendis (ASND) announced the NDA submission for TransCon CNP in achondroplasia (ACH) was accepted by the FDA with priority review with an assigned... More
